Document is current
Any future updates will be listed below
-
Authors
Fishman, Lior https://orcid.org/0000-0001-7985-7143
Modak, Avani https://orcid.org/0009-0005-2540-8170
Nechooshtan, Gal https://orcid.org/0000-0002-8994-8580
Razin, Talya
Erhard, Florian https://orcid.org/0000-0002-3574-6983
Regev, Aviv https://orcid.org/0000-0003-3293-3158
Farrell, Jeffrey A. https://orcid.org/0000-0003-4774-1562
Rabani, Michal https://orcid.org/0000-0002-8651-6096
- License Information
-
More Information
Article History
Received: 12 April 2023
Accepted: 27 March 2024
First Online: 10 April 2024
Competing interests
: A.R. is a founder and equity holder of Celsius Therapeutics, an equity holder in Immunitas Therapeutics and until August 31, 2020 was a SAB member of Syros Pharmaceuticals, Neogene Therapeutics, Asimov and ThermoFisher Scientific. From August 1, 2020, A.R. is an employee of Genentech, and has equity in Roche. All other authors declare no competing interests.
